NLG919 (CAS 1402836-58-1)
QUICK LINKS
NLG919, aslo know as 1-Cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol or CHI-E. This small molecule is known to inhibit the protein kinase CK2 and has been explored for its potential application in relation to various diseases, such as cancer, inflammation, and neurodegenerative disorders. NLG919 has been studied in relation to conditions such as type 2 diabetes and Alzheimer′s disease among other neurological disorders. The exact mechanism of action of NLG919 remains not fully understood. Nonetheless, it′s hypothesized that NLG919 curtails the activity of the protein kinase CK2, which plays a role in the regulation of several cellular processes like cell proliferation, apoptosis, and inflammation. By inhibiting CK2, NLG919 is conjectured to limit the growth of tumor cells, diminish inflammation, and yield other advantageous effects.
NLG919 (CAS 1402836-58-1) References
- Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier. | Sun, JJ., et al. 2017. Acta Pharmacol Sin. 38: 823-834. PMID: 28504251
- Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model. | Meng, X., et al. 2017. Int J Immunopathol Pharmacol. 30: 215-226. PMID: 28604143
- Hypoxia alleviation-triggered enhanced photodynamic therapy in combination with IDO inhibitor for preferable cancer therapy. | Xing, L., et al. 2019. Biomaterials. 206: 170-182. PMID: 30939409
- Folated pH-degradable nanogels for the simultaneous delivery of docetaxel and an IDO1-inhibitor in enhancing cancer chemo-immunotherapy. | Qiao, H., et al. 2019. Biomater Sci. 7: 2749-2758. PMID: 30997445
- NLG919/cyclodextrin complexation and anti-cancer therapeutic benefit as a potential immunotherapy in combination with paclitaxel. | Xu, J., et al. 2019. Eur J Pharm Sci. 138: 105034. PMID: 31382032
- Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects. | Jiang, X., et al. 2020. Int J Immunopathol Pharmacol. 34: 2058738420950584. PMID: 32962460
- Inhibition of indoleamine 2,3-dioxygenase 1 synergizes with oxaliplatin for efficient colorectal cancer therapy. | Miao, X., et al. 2021. Mol Ther Methods Clin Dev. 20: 442-450. PMID: 33665222
- Delivery of gefitinib with an immunostimulatory nanocarrier improves therapeutic efficacy in lung cancer. | Diao, D., et al. 2021. Transl Lung Cancer Res. 10: 926-935. PMID: 33718033
- Nanoconjugates to enhance PDT-mediated cancer immunotherapy by targeting the indoleamine-2,3-dioxygenase pathway. | Yang, X., et al. 2021. J Nanobiotechnology. 19: 182. PMID: 34127005
- CaCO3-Assisted Preparation of pH-Responsive Immune-Modulating Nanoparticles for Augmented Chemo-Immunotherapy. | Zhu, Y., et al. 2020. Nanomicro Lett. 13: 29. PMID: 34138248
- Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway. | Ding, Y., et al. 2021. Adv Mater. 33: e2102188. PMID: 34278622
- Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy. | Xie, X., et al. 2022. Bioact Mater. 16: 107-119. PMID: 35386322
- Bispecific prodrug nanoparticles circumventing multiple immune resistance mechanisms for promoting cancer immunotherapy. | Ye, J., et al. 2022. Acta Pharm Sin B. 12: 2695-2709. PMID: 35755274
- Hierarchical Microparticles Delivering Oxaliplatin and NLG919 Nanoprodrugs for Local Chemo-immunotherapy. | Zhang, Q., et al. 2022. ACS Appl Mater Interfaces. 14: 48527-48539. PMID: 36263713
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NLG919, 10 mg | sc-478118 | 10 mg | $352.00 |